Gilead Sciences Hits Day High with Strong 3.6% Intraday Surge

Gilead Sciences, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has shown significant activity today, gaining 3.6% as of February 27, 2026. The stock reached an intraday high of USD 150.00, reflecting its robust market performance. Over the past year, Gilead has delivered a remarkable return of 33.0%, outperforming the S&P 500, which recorded a gain of 17.36%. The company's strong fundamentals are highlighted by a high Return on Capital Employed (ROCE) of 26.79%, indicating efficient management and operational strength. Additionally, Gilead's low Debt to EBITDA ratio of 1.56 times underscores its strong ability to service debt, further enhancing its financial stability. Institutional holdings stand at a notable 89.94%, suggesting confidence from large investors in the company's long-term prospects. Gilead's performance metrics, including a P/E ratio of 16.00 and a dividend yield of 2.10%, position it favorably within its industry. Overall, Gilead Sciences continues to demonstrate resilience and strong market presence amidst fluctuating market conditions.